Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK pays $5m in Isis Pharma pact
The milestone payment triggers from the initiation of a Phase 1 clinical trial of ISIS-TTRRx, an antisense drug, by Isis Pharma to treat transthyretin amyloidosis. The agreement allows
The milestone payment triggers from the initiation of a Phase 1 clinical trial of ISIS-TTRRx, an antisense drug, by Isis Pharma to treat transthyretin amyloidosis. The agreement allows
The company expects to recruit around 880 patients in 48 hospitals in 9 countries across three continents. The study, named as immunotherapy Multikine anti tumor treatments (IT-MATTERS), is
The new development is particularly suitable for processing highly effective inhalation products within filling ranges of 2-30 milligrams. The GKF 2500 is available with a dosing roller which
The expanded facility features a 90-bed sleeping area, exam and procedure rooms, pharmacy, in-patient and outpatient fully equipped laboratories and attractive and comfortable subject spaces with recreational areas,
Following the acquisition, Phadia will be part of Thermo Fisher’s Specialty Diagnostics business within its Analytical Technologies Segment. Thermo Fisher will leverage Phadia’s clinical marketing model to sell
ShangPharma has reported a net income of $3.01m, or $0.16 per diluted share, compared to net income of $2.73m or $0.18 per diluted share, for the same period
Under the agreement, both the companies will develop fluid systems and market single-use tubing, which will be produced by Raumedic and will supply to SSB. SSB will combine
APP Pharmaceuticals develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. Gemcitabine HCI for Injection is indicated
RG3039, an orally bioavailable compound, is an inhibitor of an RNA processing enzyme which targets SMN2. The trial is designed to investigate the safety and pharmacokinetic of escalating
The results of the trial suggested that olaparib 400mg twice daily extended progression free survival (PFS) by RECIST compared to placebo Median PFS: 8.4 vs 4.8 months respectively.